MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,666.45
+0.19%
NASDAQ 100
$30,501.56
+0.31%
DOW JONES
$50,927.00
+0.04%
NASDAQ Composite
$26,871.60
+0.04%
RUSSELL 2000
$2,790.20
+0.41%
CBOE VIX
$16.39
+0.31%
Sector Heatmap
Technology+1.05%
Financials+0.11%
Healthcare-1.32%
Consumer Cycl-0.03%
Consumer Staples-0.33%
Energy+1.95%
Industrials+0.99%
Materials-0.33%
Real Estate-0.56%
Utilities+0.61%
Comm Services-0.93%
ACRS — Aclaris Therapeutics, Inc.
NasdaqAclaris Therapeutics, Inc.
$4.41
-0.85(-16.16%)
- O
- 5.18
- H
- 5.18
- L
- 4.35
- V
- 5.09M
⏱️ End-of-day dataAs of Oct 1, 2026
Aclaris Therapeutics, Inc. Statistics
Total Valuation
| Market Cap | $758.07M |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | 139.82M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | 0.40 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | 56.32% |
| Return on Assets (ROA) | -99.76% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-271,562 |
| Employee Count | 73 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | +135.83% |
| 50-Day Moving Average | $5.73 |
| 200-Day Moving Average | $4.44 |
| Relative Strength Index (RSI) | 35.56 |
| Average Volume (20 Days) | 2,948,732 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | $208.00K |
| Operating Income | -$22.19M |
| Pretax Income | -$19.82M |
| Net Income | -$19.82M |
| EBITDA | -$22.09M |
| EBIT | -$22.19M |
| Loss Per Share | $-0.15 |
Balance Sheet
| Cash & Cash Equivalents | $28.66M |
| Total Debt | n/a |
| Net Cash | n/a |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -$35.20M |
| Book Value Per Share | $-0.25 |
| Working Capital | -$16.35M |
Cash Flow
| Operating Cash Flow | -$15.12M |
| Capital Expenditures | -$13.00K |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -$18.16M |
| FCF Per Share | $-0.13 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | -2.40% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |